Lin Junyu, Pang Dejiang, Li Chunyu, Ou Ruwei, Yu Yujiao, Cui Yiyuan, Huang Jingxuan, Shang Huifang
Laboratory of Neurodegenerative Disorders, Department of Neurology, Rare Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Department of Neurology, West China Hospital, Sichuan University, Guoxue Road No. 37, Chengdu, Sichuan 610041, China.
Ther Adv Neurol Disord. 2024 May 19;17:17562864241252713. doi: 10.1177/17562864241252713. eCollection 2024.
The calcium channel has been considered to have great potential as a drug target for neuroprotective therapy in Parkinson's disease (PD), but previous studies yielded inconsistent results.
This study aimed to conduct a systematic review and meta-analysis to assess the relationship between using calcium channel blockers (CCBs) and the risk and progression of PD.
The terms such as 'Parkinson's disease', 'PD', 'calcium channel blockers', and 'CCB' were used to search the literature published before 1 May 2023 in English databases, including PubMed, Embase, and Cochrane Library, for studies on CCB and PD. Data analysis was performed using Review Manager 5.3 software.
A total of 190 works of literature were preliminarily retrieved, and 177 works of literature were excluded by eliminating duplicates, reading abstracts, and reading full texts. A total of nine studies were finally included in the meta-analysis of the CCB and the risk of PD, and five studies were included in the systematic review of the CCB and the progression of PD. A total of 2,961,695 participants were included in the meta-analysis. The random-effects model was used for analysis due to significant heterogeneity. The main results of the meta-analysis showed that the use of CCB could reduce the risk of PD (relative risk 0.78, 95% confidence interval 0.62-0.99).
CCB use was associated with a significantly reduced risk of PD. Whether CCB use has a disease-modifying effect on PD needs further study.
PROSPERO: CRD42024508242.
钙通道被认为作为帕金森病（PD）神经保护治疗的药物靶点具有巨大潜力，但先前的研究结果并不一致。
本研究旨在进行系统评价和荟萃分析，以评估使用钙通道阻滞剂（CCB）与PD风险及病情进展之间的关系。
使用“帕金森病”“PD”“钙通道阻滞剂”“CCB”等术语，检索截至2023年5月1日在英文数据库（包括PubMed、Embase和Cochrane图书馆）中发表的关于CCB与PD的研究。使用Review Manager 5.3软件进行数据分析。
初步检索到190篇文献，通过去除重复文献、阅读摘要和全文，排除了177篇文献。最终共有9项研究纳入CCB与PD风险的荟萃分析，5项研究纳入CCB与PD病情进展的系统评价。荟萃分析共纳入2,961,695名参与者。由于存在显著异质性，采用随机效应模型进行分析。荟萃分析的主要结果显示，使用CCB可降低PD风险（相对风险0.78，95%置信区间0.62 - 0.99）。
使用CCB与显著降低PD风险相关。CCB对PD是否具有疾病修饰作用需要进一步研究。
PROSPERO：CRD42024508242
